TY - JOUR T1 - Structural inequalities in the pathway to COVID-19 immunity JF - medRxiv DO - 10.1101/2021.10.06.21264573 SP - 2021.10.06.21264573 AU - Isobel Routledge AU - Saki Takahashi AU - Adrienne Epstein AU - Jill Hakim AU - Owen Janson AU - Keirstinne Turcios AU - Jo Vinden AU - John Tomas Risos AU - Margaret Rose Baniqued AU - Lori Pham AU - Clara Di Germanio AU - Michael Busch AU - Margot Kushel AU - Bryan Greenhouse AU - Isabel Rodríguez-Barraquer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264573.abstract N2 - Disease outbreaks often highlight existing inequalities and injustices within society. The COVID-19 pandemic has underscored long-existing health inequalities, both within countries and between the Global North and South. These disparities have been observed throughout the pandemic, from disparities in the severity and impact of the initial waves of cases to disparities in who was most protected during the roll-out of vaccination (1–3). As the Delta variant surges in many countries, structural inequalities shape the trajectory of the pandemic and exacerbate existing health disparities. In the age of vaccination, the “double burden” of disparities in both exposure to infection and vaccination coverage intersect to determine the current and future patterns of infection, immunity, and mortality. It is important to consider the ways in which these disparities, with overlapping but distinct drivers, interact to determine population-level immunity and the burden of COVID-19 in different communities. Individuals or communities can experience different pathways to immunity, whether through infection, vaccination, or both. Using San Francisco as a case study, we show how a sero-epidemiological approach can illuminate disparities in the “pathway to immunity”.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge sources of funding support, including from the Schmidt Science Fellows, in partnership with the Rhodes Trust (ST); Chan Zuckerberg Biohub Investigator program (BG); the ZSFG Department of Medicine and Division of HIV, ID, and Global Medicine; the MIDAS Coordination Center COVID-19 Urgent Grant Program (MIDASNI2020-5) by a grant from the National Institute of General Medical Science (3U24GM132013-02S2) (IR, ST, IRB); and the National Institutes of Health/National Institute of General Medical Sciences R35GM138361-02 (IRB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received expedited review approval by the UCSF IRB #20-30379 (Serological Surveillance of SARS-CoV-2 in Residual Serum/Plasma Samples).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code to generate results will be available at https://github.com/EPPIcenter/scale-it-2 ER -